These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1298959)

  • 21. [Acetylation polymorphism in lung cancer].
    Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
    An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The role of genetically determined acetylation of drugs and xenobiotics in pathogenesis of neoplastic diseases].
    Niewiński P; Orzechowska-Juzwenko K
    Postepy Hig Med Dosw; 1996; 50(2):131-43. PubMed ID: 8848422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics and its clinical implications: N-acetylation polymorphism.
    Horai Y; Ishizaki T
    Ration Drug Ther; 1987 Oct; 21(10):1-7. PubMed ID: 3326026
    [No Abstract]   [Full Text] [Related]  

  • 25. Acetylator status, drug metabolism and disease.
    Pande JN; Pande A; Singh SP
    Natl Med J India; 2003; 16(1):24-6. PubMed ID: 12715953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
    Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
    Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Genotypic differences in the level of N-acetyltransferase activity in mice of inbred lines and their hybrids].
    Bulovskaia LN; Kaĭdanov LZ
    Genetika; 1991 Jul; 27(7):1206-11. PubMed ID: 1756957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfadimidine and isoniazid loading in man and laboratory rats. Pharmacokinetic and pharmacogenetic results on drug acetylation.
    Dubbels R; Kattner E; Sell-Maurer D; Schloot W
    Arzneimittelforschung; 1980; 30(9):1574-9. PubMed ID: 7193028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-acetylation phenotyping with sulfamethazine in an Iranian population.
    Sardaş S; Lahijany B; Cok I; Karakaya AE
    Pharmacogenetics; 1993 Jun; 3(3):131-4. PubMed ID: 8334437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
    Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
    Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical aspects of the polymorphism of oxidation phenotype].
    Mrozikiewicz PM
    Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):608-10. PubMed ID: 1488339
    [No Abstract]   [Full Text] [Related]  

  • 32. [Genetic polymorphism of acetylation and hydroxylation in the Briton population].
    Bressollette L; Berthou F; Riche C; Mottier D; Floch HH
    Therapie; 1990; 45(2):99-103. PubMed ID: 2353336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically determined variability in drug metabolism: dual slow acetylation and drug oxidation traits.
    Mahgoub A; Idle JR; Smith RL
    Lancet; 1979 Jul; 2(8134):154. PubMed ID: 88594
    [No Abstract]   [Full Text] [Related]  

  • 34. The relation of cellular oxidation to cancer.
    WILLIAMS G
    J Int Coll Surg; 1951 Apr; 15(4):488-97. PubMed ID: 14824605
    [No Abstract]   [Full Text] [Related]  

  • 35. [Modern views on cancer].
    KOSIR A
    Med Glas; 1957; 11(7-8):245-7. PubMed ID: 13503479
    [No Abstract]   [Full Text] [Related]  

  • 36. [Polymorphism of acetylation and oxidation phenotypes and the risk of neoplasms--pharmacogenetic approach to the epidemiology of neoplasms].
    Mrozikiewicz PM
    Postepy Hig Med Dosw; 1992; 46(5):531-6. PubMed ID: 1298959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acetylation and oxidation phenotypes in insulin-dependent diabetes mellitus.
    Mrozikiewicz A; Kiełczewska-Mrozikiewicz D; Lowicki Z; Chmara E; Mrozikiewicz PM; Jabłecka A; Kaźmierczak E; Andrys I
    Mater Med Pol; 1995; 27(4):147-9. PubMed ID: 9000838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic polymorphism of drug metabolism.
    Paxton JW
    N Z Med J; 1984 Aug; 97(762):567-9. PubMed ID: 6591031
    [No Abstract]   [Full Text] [Related]  

  • 40. [N-acetyltransferase genetic polymorphism and its role in the development of neoplastic disease].
    Lutz W
    Med Pr; 2000; 51(3):277-84. PubMed ID: 11002474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.